PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.92%
Revenue growth above 1.5x 3088.T's 3.27%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
5.52%
Gross profit growth at 75-90% of 3088.T's 6.48%. Bill Ackman would demand operational improvements to match competitor gains.
29.29%
EBIT growth 75-90% of 3088.T's 35.13%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
35.99%
Operating income growth 1.25-1.5x 3088.T's 26.41%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
30.23%
Net income growth at 75-90% of 3088.T's 36.29%. Bill Ackman would press for improvements to catch or surpass competitor performance.
30.21%
EPS growth at 75-90% of 3088.T's 36.28%. Bill Ackman would push for improved profitability or share repurchases to catch up.
30.21%
Diluted EPS growth at 75-90% of 3088.T's 36.28%. Bill Ackman would expect further improvements in net income or share count reduction.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
57.27%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 40.18%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
-14.00%
Negative 5Y CAGR while 3088.T stands at 22.23%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
37.58%
3Y revenue/share CAGR above 1.5x 3088.T's 12.40%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
100.00%
Positive long-term OCF/share growth while 3088.T is negative. John Neff would see a structural advantage in sustained cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
204.55%
Similar net income/share CAGR to 3088.T's 202.61%. Walter Schloss would see parallel tailwinds or expansions for both firms.
1.06%
Below 50% of 3088.T's 71.83%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
46.13%
Below 50% of 3088.T's 96.35%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
174.00%
10Y equity/share CAGR above 1.5x 3088.T's 112.21%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
20.89%
Below 50% of 3088.T's 65.35%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
67.68%
3Y equity/share CAGR above 1.5x 3088.T's 31.59%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.00%
Firm’s AR is declining while 3088.T shows 14.34%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.71%
Inventory shrinking or stable vs. 3088.T's 2.65%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
0.86%
Asset growth well under 50% of 3088.T's 1.92%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.21%
Similar to 3088.T's 3.20%. Walter Schloss finds parallel capital usage or profit distribution strategies.
20.57%
Debt growth of 20.57% while 3088.T is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-0.12%
We cut SG&A while 3088.T invests at 2.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.